Oppenheimer & Co. Inc. Purchases 25,295 Shares of DermTech, Inc. (NASDAQ:DMTK)

Oppenheimer & Co. Inc. grew its position in DermTech, Inc. (NASDAQ:DMTKFree Report) by 253.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 35,295 shares of the company’s stock after buying an additional 25,295 shares during the period. Oppenheimer & Co. Inc. owned 0.11% of DermTech worth $130,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of DMTK. Gateway Wealth Partners LLC purchased a new position in shares of DermTech in the 1st quarter valued at approximately $273,000. White Pine Capital LLC raised its position in shares of DermTech by 21.9% in the 1st quarter. White Pine Capital LLC now owns 259,178 shares of the company’s stock valued at $954,000 after purchasing an additional 46,504 shares during the last quarter. Triatomic Management LP raised its position in shares of DermTech by 21.6% in the 1st quarter. Triatomic Management LP now owns 154,652 shares of the company’s stock valued at $569,000 after purchasing an additional 27,444 shares during the last quarter. Kovack Advisors Inc. purchased a new position in shares of DermTech in the 1st quarter valued at approximately $43,000. Finally, Trellus Management Company LLC purchased a new position in shares of DermTech in the 1st quarter valued at approximately $137,000. 27.81% of the stock is currently owned by institutional investors.

DermTech Trading Down 4.2 %

DMTK opened at $2.30 on Friday. DermTech, Inc. has a 12-month low of $1.55 and a 12-month high of $6.44. The firm has a market capitalization of $77.51 million, a PE ratio of -0.59 and a beta of 2.18. The firm has a 50 day moving average of $2.77 and a two-hundred day moving average of $3.18.

DermTech (NASDAQ:DMTKGet Free Report) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.04). DermTech had a negative return on equity of 99.14% and a negative net margin of 853.02%. The business had revenue of $3.98 million for the quarter, compared to analysts’ expectations of $3.55 million. As a group, analysts predict that DermTech, Inc. will post -3.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, BTIG Research decreased their price objective on shares of DermTech from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, August 7th.

Check Out Our Latest Stock Report on DermTech

DermTech Company Profile

(Free Report)

DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers.

Further Reading

Want to see what other hedge funds are holding DMTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DermTech, Inc. (NASDAQ:DMTKFree Report).

Institutional Ownership by Quarter for DermTech (NASDAQ:DMTK)

Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.